[Application of prostaglandin E1 and Naftidrofuryl in combined treatment of purulent-necrotic complications of the diabetic foot syndrome].
Girka
E I
EI
Bazarinskaia
Z I
ZI
Kravtsov
E A
EA
D000527:Alprostadil / Q000627:therapeutic use*; D017719:Diabetic Foot / Q000150:complications*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009257:Nafronyl / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014946:Wound Infection / Q000188:drug therapy* / Q000209:etiology*
D014665:Vasodilator Agents; D009257:Nafronyl; D000527:Alprostadil